Clinical trials: TNBC, Triple Negative Breast Cancer
Breast Cancer Triple Negative, Breast Cancer Stage II
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
This research study is a prospective, single arm, pilot study, designed to evaluate the correlation between the immune and clinical responses of subjects with untreated Stage II-III triple negative breast cancer (TNBC) undergoing…
- Conditions
- Breast Cancer Triple Negative, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive
- Trial name
- NCT05877859
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Emory University
Triple Negative Breast Cancer
Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women
A key tenet of this project is that of reaching translational human diagnosis and biomarker end points. To lay a foundation and make progress towards these translational goals, investigators will address the following specific…
- Trial name
- NCT04291950
- Testing
- Needle core biopsy
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Arizona
Breast Cancer, Breast Diseases
The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer
This study will look at effects the combination of palbociclib and dose-dense neoadjuvant chemotherapy may have on triple negative breast cancer tumours which have not yet been treated.
- Conditions
- Breast Cancer, Breast Diseases, Breast Neoplasms
- Trial name
- PECP (NCT03756090)
- Testing
- Palbociclib, Epirubicin, Cyclophosphamide
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Triple Negative Breast Cancer, HER2-positive Breast Cancer
Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer
Patients with Her-2 positive and triple negative breast cancer who received neoadjuvant chemotherapy will be included in the study.
- Trial name
- NCT05169853
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Triple Negative Breast Cancer, Immune Checkpoint Inhibitor
LAG3 Expression in Triple Negative Breast Cancer
This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.
- Trial name
- NCT06259162
- Testing
- LAG-3 expression / immune checkpoint protein expression
- Where
- South Korea
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Breast Cancer, Triple Negative Breast Cancer
Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy
Neoadjuvant chemotherapy (NACT) is administered to treat invasive breast cancer before surgery. It offers the opportunity to evaluate tumor response to treatment in aggressive disease, and guide additional therapies for patients…
- Trial name
- NCT03750240
- Testing
- Sodium (Na) Magnetic Resonance Imaging (MRI), Dynamic Contrast- Enhanced (DCE) MRI
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Metastatic Triple Negative Breast Cancers
Sac-TMT for Active TNBC Brain Metastases
This is a multi-site prospective single-arm open-label phase 2 clinical trial including 20 participants with metastatic TNBC and active brain metastases to be treated with sacituzumab tirumotecan 4 mg/kg IV on Days 1, and 15 of…
- Trial name
- BERLIN (NCT07458113)
- Testing
- Sacituzumab tirumotecan
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Yale University
BRCA1 Hereditary Breast and Ovarian Cancer Syndrome
Neoadjuvant Carboplatin in Triple Negative Breast Cancer
Breast cancer is the most frequent neoplasm in women in Brazil and in the world and up to 15% of all cases diagnosed correspond to the triple negative subtype.
- Trial name
- NCT02978495
- Testing
- Doxorubicin, Carboplatin, Paclitaxel
- Where
- Brazil
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Barretos Cancer Hospital
HER2-positive Breast Cancer, HER2 Low
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
This is an open-label, single-arm, multi-site phase I/Ib trial with SYD985, an antibody-drug conjugate (ADC) targeting HER2 on the cell membrane, combined with paclitaxel.
- Conditions
- HER2-positive Breast Cancer, HER2 Low, SYD-985, SYD985
- Trial name
- NCT04602117
- Testing
- Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- QuantumLeap Healthcare Collaborative
Triple Negative Breast Cancer, HER2-positive Breast Cancer
Exosome as the Prognostic and Predictive Biomarker in EBC Patients
This study is the experimental study for serial ctDNA and exosome evaluation in EBC patients
- Trial name
- NCT05955521
- Testing
- exosome and ctDNA evaluation
- Where
- South Korea
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
The purpose of this study is to determine the safety as well as the most effective dose of the alpha-lactalbumin vaccine (aLA breast cancer vaccine) to treat patients with non-metastatic triple negative breast cancer…
- Conditions
- Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Residual Disease
- Trial name
- NCT04674306
- Testing
- α-lactalbumin vaccine, Zymosan
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- George T. Budd
Carcinoma Breast Stage IV
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT02183805
- Testing
- Abraxane,Cyclophosphamide,Carboplatin
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Breast Cancer
Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy
In our study; investigator aim To show efficacy and toxicity of Adjuvant cisplatin and gemcitabine in triple-negative breast cancer patients with non pathologically complete response after neoadjuvant chemotherapy To compare…
- Trial name
- NCT06268327
- Testing
- Cisplatin injection and gemcitabine, Capecitabine tablets
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Assiut University
TNBC - Triple-Negative Breast Cancer
Targeting Metastatic Breast Cancers by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinical Trial
The diverse group of breast tumors known as triple-negative breast cancer (TNBC) which is lethally and deadly type of breast cancer and insensitive to endocrine therapy and HER2-targeted therapy because it lacks the expression of…
- Trial name
- NCT05957939
- Testing
- Alkaline Glucosodiene Molecules
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Ministry of Health, Saudi Arabia
Metastatic Triple-negative Breast Cancer
Saci Nivo Rela for TNBC
This is a randomized, open-label, phase Ib study to assess safety and efficacy of sacituzumab govitecan plus nivolumab or sacituzumab govitecan plus a fixed dose combination of nivolumab and relatlimab in patients with any…
- Trial name
- SIMONE (NCT06963905)
- Testing
- Relatlimab FDC + Nivolumab, Sacituzumab Govitecan (SG), Nivolumab
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yale University
Breast Cancer, Hereditary Breast and Ovarian Cancer
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).
- Trial name
- PROGECT (NCT02302742)
- Where
- 11 sites in United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Chemoprevention
Effect of Resveratrol on Serum IGF2 Among African American Women
African American (AA) women with breast cancer (BC) have higher mortality and are associated with worse outcomes when treated with available adjuvant treatments.
- Trial name
- NCT04266353
- Testing
- Resveratrol (RSV)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Loma Linda University
Breast Cancer
A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC
This is a phase II, explorative, open-labeled, multi-centered, double-arm, investigator-initiated clinical trial of Camrelizumab (an anti-PD-1 antibody) in combination with Nab-paclitaxel (a chemotherapeutic agent against breast…
- Trial name
- NCT06632405
- Testing
- Camrelizumab, Nab paclitaxel, Levocetirizine Hydrochloride
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Triple Negative Breast Cancer
Correlation Between TILs and Blood Cell Counts in Triple Negative Breast Cancer Patients
The PERCEPTION study aims to assess the correlation between blood cell counts (Leucocytes, Neutrophils, Lymphocytes, Platelets, NLR (Neutrophil-to-Lymphocyte Ratio) and PLR (Platelet-to-Lymphocyte Ratio)) and Tumor Infiltrating…
- Trial name
- PERCEPTION (NCT04068623)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Centre Jean Perrin